TipRanks
Merck & Company (IT:1MRKX)
:1MRKX
Italy Market
1MRKX
Merck & Company
RESEARCH TOOLSreports

Merck & Company (1MRKX) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

1MRKX Analyst Ratings

Moderate Buy
21Ratings
Moderate Buy
15 Buy
6 Hold
0 Sell
Based on 21 analysts giving stock ratings to
Merck
& Company
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1MRKX Stock 12 Month Forecast

Average Price Target

€144.34
▲(12.16% Upside)
Based on 21 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is €144.34 with a high forecast of €160.71 and a low forecast of €93.75. The average price target represents a 12.16% change from the last price of €128.70.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"70":"€70","161":"€161","92.75":"€92.8","115.5":"€115.5","138.25":"€138.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":160.7129946,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€160.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":144.34407848333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€144.34</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":93.74924685,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€93.75</span>\n  </div></div>","useHTML":true}}],"tickPositions":[70,92.75,115.5,138.25,161],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,128.94,131.3840765076923,133.8281530153846,136.27222952307693,138.71630603076923,141.16038253846153,143.60445904615383,146.04853555384616,148.49261206153847,150.93668856923077,153.38076507692307,155.8248415846154,158.2689180923077,{"y":160.7129946,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,128.94,130.12492911410257,131.30985822820512,132.4947873423077,133.67971645641026,134.8646455705128,136.04957468461538,137.23450379871795,138.41943291282053,139.60436202692307,140.78929114102564,141.97422025512822,143.15914936923076,{"y":144.34407848333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,128.94,126.23301898846154,123.52603797692308,120.81905696538462,118.11207595384616,115.4050949423077,112.69811393076924,109.99113291923078,107.28415190769232,104.57717089615386,101.8701898846154,99.16320887307693,96.45622786153847,{"y":93.74924685,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":73.438,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.689,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.163,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.577,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.378,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.295,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.86,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.028,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.302,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.622,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.689,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.939,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.94,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€160.71Average Price Target€144.34Lowest Price Target€93.75
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on IT:1MRKX
Jason Gerberry
Bank of America Securities
Bank of America Securities
€145.53→€147.32
Buy
14.47%
Upside
Reiterated
10/30/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK) and Illumina (NASDAQ: ILMN)
BMO Capital Analyst forecast on IT:1MRKX
Evan Seigerman
BMO Capital
BMO Capital
€151.78
Buy
17.94%
Upside
Reiterated
10/30/26
Merck & Company (MRK) Gets a Buy from BMO Capital
Morgan Stanley Analyst forecast on IT:1MRKX
Terence Flynn
Morgan Stanley
Morgan Stanley
€158.03→€155.36
Buy
20.71%
Upside
Assigned
10/30/26
Morgan Stanley Gives a Buy Rating to Merck & Company (MRK)
Scotiabank Analyst forecast on IT:1MRKX
Louise Chen
Scotiabank
Scotiabank
€160.71
Buy
24.87%
Upside
Assigned
10/30/26
Analysts Are Bullish on These Healthcare Stocks: Viemed Healthcare (VMD), IDEAYA Biosciences (IDYA)
J.P. Morgan Analyst forecast on IT:1MRKX
Chris Schott
J.P. Morgan
J.P. Morgan
€147.32→€156.25
Buy
21.41%
Upside
Assigned
10/30/26
Merck price target raised to $175 from $165 at JPMorganMerck price target raised to $175 from $165 at JPMorgan
Guggenheim Analyst forecast on IT:1MRKX
Vamil Divan
Guggenheim
Guggenheim
€151.78→€152.68
Buy
18.63%
Upside
Reiterated
10/29/26
Merck & Company (MRK) Receives a Buy from Guggenheim
Barclays Analyst forecast on IT:1MRKX
Emily Field
Barclays
Barclays
€160.71
Buy
24.87%
Upside
Reiterated
10/28/26
Barclays Keeps Their Buy Rating on Merck & Company (MRK)
RBC Capital Analyst forecast on IT:1MRKX
Trung Huynh
RBC Capital
RBC Capital
€129.46
Hold
0.59%
Upside
Reiterated
10/27/26
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (NASDAQ: COGT), Merck & Company (NYSE: MRK) and Alnylam Pharma (NASDAQ: ALNY)
Citi Analyst forecast on IT:1MRKX
Geoff Meacham
Citi
Citi
€129.46
Hold
0.59%
Upside
Reiterated
10/27/26
Merck: Emerging Oncology Pipeline Encouraging but Still Early; Risk/Reward Balanced with Price Target Maintained at $145
Wells Fargo Analyst forecast on IT:1MRKX
Mohit Bansal
Wells Fargo
Wells Fargo
€147.32
Buy
14.47%
Upside
Reiterated
10/26/26
Merck & Company (MRK) Receives a Buy from Wells Fargo
Cantor Fitzgerald Analyst forecast on IT:1MRKX
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
€129.46
Hold
0.59%
Upside
Reiterated
10/26/26
Merck & Company (MRK) Gets a Hold from Cantor Fitzgerald
Bernstein Analyst forecast on IT:1MRKX
Courtney Breen
Bernstein
Bernstein
€93.75
Hold
-27.16%
Downside
Reiterated
10/25/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Erasca (NASDAQ: ERAS) and Incyte (NASDAQ: INCY)
UBS Analyst forecast on IT:1MRKX
Michael Yee
UBS
UBS
€156.25
Buy
21.41%
Upside
Reiterated
10/24/26
Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (NASDAQ: AVBP) and Merck & Company (NYSE: MRK)
Goldman Sachs Analyst forecast on IT:1MRKX
Asad Haider
Goldman Sachs
Goldman Sachs
€138.39
Buy
7.53%
Upside
Reiterated
10/22/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK) and Thermo Fisher (NYSE: TMO)
Leerink Partners Analyst forecast on IT:1MRKX
Daina Graybosch
Leerink Partners
Leerink Partners
€143.75
Buy
11.69%
Upside
Reiterated
10/12/26
Merck & Company (MRK) Gets a Buy from Leerink Partners
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on IT:1MRKX
Jason Gerberry
Bank of America Securities
Bank of America Securities
€145.53→€147.32
Buy
14.47%
Upside
Reiterated
10/30/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK) and Illumina (NASDAQ: ILMN)
BMO Capital Analyst forecast on IT:1MRKX
Evan Seigerman
BMO Capital
BMO Capital
€151.78
Buy
17.94%
Upside
Reiterated
10/30/26
Merck & Company (MRK) Gets a Buy from BMO Capital
Morgan Stanley Analyst forecast on IT:1MRKX
Terence Flynn
Morgan Stanley
Morgan Stanley
€158.03→€155.36
Buy
20.71%
Upside
Assigned
10/30/26
Morgan Stanley Gives a Buy Rating to Merck & Company (MRK)
Scotiabank Analyst forecast on IT:1MRKX
Louise Chen
Scotiabank
Scotiabank
€160.71
Buy
24.87%
Upside
Assigned
10/30/26
Analysts Are Bullish on These Healthcare Stocks: Viemed Healthcare (VMD), IDEAYA Biosciences (IDYA)
J.P. Morgan Analyst forecast on IT:1MRKX
Chris Schott
J.P. Morgan
J.P. Morgan
€147.32→€156.25
Buy
21.41%
Upside
Assigned
10/30/26
Merck price target raised to $175 from $165 at JPMorganMerck price target raised to $175 from $165 at JPMorgan
Guggenheim Analyst forecast on IT:1MRKX
Vamil Divan
Guggenheim
Guggenheim
€151.78→€152.68
Buy
18.63%
Upside
Reiterated
10/29/26
Merck & Company (MRK) Receives a Buy from Guggenheim
Barclays Analyst forecast on IT:1MRKX
Emily Field
Barclays
Barclays
€160.71
Buy
24.87%
Upside
Reiterated
10/28/26
Barclays Keeps Their Buy Rating on Merck & Company (MRK)
RBC Capital Analyst forecast on IT:1MRKX
Trung Huynh
RBC Capital
RBC Capital
€129.46
Hold
0.59%
Upside
Reiterated
10/27/26
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (NASDAQ: COGT), Merck & Company (NYSE: MRK) and Alnylam Pharma (NASDAQ: ALNY)
Citi Analyst forecast on IT:1MRKX
Geoff Meacham
Citi
Citi
€129.46
Hold
0.59%
Upside
Reiterated
10/27/26
Merck: Emerging Oncology Pipeline Encouraging but Still Early; Risk/Reward Balanced with Price Target Maintained at $145
Wells Fargo Analyst forecast on IT:1MRKX
Mohit Bansal
Wells Fargo
Wells Fargo
€147.32
Buy
14.47%
Upside
Reiterated
10/26/26
Merck & Company (MRK) Receives a Buy from Wells Fargo
Cantor Fitzgerald Analyst forecast on IT:1MRKX
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
€129.46
Hold
0.59%
Upside
Reiterated
10/26/26
Merck & Company (MRK) Gets a Hold from Cantor Fitzgerald
Bernstein Analyst forecast on IT:1MRKX
Courtney Breen
Bernstein
Bernstein
€93.75
Hold
-27.16%
Downside
Reiterated
10/25/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Erasca (NASDAQ: ERAS) and Incyte (NASDAQ: INCY)
UBS Analyst forecast on IT:1MRKX
Michael Yee
UBS
UBS
€156.25
Buy
21.41%
Upside
Reiterated
10/24/26
Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (NASDAQ: AVBP) and Merck & Company (NYSE: MRK)
Goldman Sachs Analyst forecast on IT:1MRKX
Asad Haider
Goldman Sachs
Goldman Sachs
€138.39
Buy
7.53%
Upside
Reiterated
10/22/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK) and Thermo Fisher (NYSE: TMO)
Leerink Partners Analyst forecast on IT:1MRKX
Daina Graybosch
Leerink Partners
Leerink Partners
€143.75
Buy
11.69%
Upside
Reiterated
10/12/26
Merck & Company (MRK) Gets a Buy from Leerink Partners
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AMRXAmneal Pharmaceuticals
DNTHDianthus Therapeutics
REPLReplimune Group
VSTMVerastem
OVIDOvid Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merck & Company

3 Months
Asad HaiderGoldman Sachs
Success Rate
14/15 ratings generated profit
93%
Average Return
+10.04%
Copying Asad Haider's trades and holding each position for 3 Months would result in 93.33% of your transactions generating a profit, with an average return of +10.04% per trade.
1 Year
Asad HaiderGoldman Sachs
Success Rate
15/15 ratings generated profit
100%
Average Return
+34.91%
Copying Asad Haider's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +34.91% per trade.
2 Years
Asad HaiderGoldman Sachs
Success Rate
15/15 ratings generated profit
100%
Average Return
+41.54%
Copying Asad Haider's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +41.54% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1MRKX Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
1
0
0
0
0
Buy
43
44
52
54
64
Hold
18
16
16
17
23
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
62
60
68
71
87
In the current month, 1MRKX has received 64 Buy Ratings, 23 Hold Ratings, and 0 Sell Ratings. 1MRKX average Analyst price target in the past 3 months is 144.34.
Each month's total comprises the sum of three months' worth of ratings.

1MRKX Financial Forecast

1MRKX Earnings Forecast

Next quarter’s earnings estimate for 1MRKX is €1.60 with a range of €1.53 to €1.75. The previous quarter’s EPS was €2.22. 1MRKX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1MRKX has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1MRKX is €1.60 with a range of €1.53 to €1.75. The previous quarter’s EPS was €2.22. 1MRKX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1MRKX has Performed in-line its overall industry.

1MRKX Sales Forecast

Next quarter’s sales forecast for 1MRKX is €14.62B with a range of €14.21B to €14.96B. The previous quarter’s sales results were €16.14B. 1MRKX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1MRKX has Performed in-line its overall industry.
Next quarter’s sales forecast for 1MRKX is €14.62B with a range of €14.21B to €14.96B. The previous quarter’s sales results were €16.14B. 1MRKX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1MRKX has Performed in-line its overall industry.

1MRKX Stock Forecast FAQ

What is IT:1MRKX’s average 12-month price target, according to analysts?
Based on analyst ratings, Merck & Company’s 12-month average price target is 144.34.
    What is IT:1MRKX’s upside potential, based on the analysts’ average price target?
    Merck & Company has 12.16% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Merck & Company a Buy, Sell or Hold?
          Merck & Company has a consensus rating of Moderate Buy, which is based on 15 buy ratings, 6 hold ratings and 0 sell ratings.
            What is Merck & Company’s share price target?
            The average share price target for Merck & Company is 144.34. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €160.71 ,and the lowest forecast is €93.75. The average share price target represents 12.16% Increase from the current price of €128.7.
              What do analysts say about Merck & Company?
              Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.
                How can I buy shares of Merck & Company?
                To buy shares of IT:1MRKX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.